Will AstraZeneca plc, Shanks Group plc And Sports Direct International Plc Make Storming Comebacks?

Are these 3 stocks worthy of ‘turnaround’ status? AstraZeneca plc (LON: AZN), Shanks Group plc (LON: SKS) and Sports Direct International Plc (LON: SPD).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in waste disposal company Shanks (LSE: SKS) have fallen by 4% today after it released a profit warning. Its update stated that market conditions in the oil, gas and electricity sectors have been challenging and this means that it now expects to miss forecasts for the full year. It also separately announced the sale of a non-core asset for £30m.

Despite the difficult trading conditions, Shanks’ commercial division has continued to deliver strong profit growth, driven by the company’s self-help initiatives. And its hazardous waste division has also traded robustly despite the deterioration in the oil and gas sector, which makes up around half of its sales. But with Shanks’ municipal division delivering worse performance than expected, its near-term outlook remains very challenging.

Looking ahead, Shanks was expected to post a fall in earnings of 5% prior to today’s update. As such, investor sentiment could worsen in the near term as the market begins to price-in an additional deterioration in its profit outlook. And even though Shanks is expected to rebound with double-digit earnings growth next year, its price-to-earnings (P/E) ratio of 17.7 indicates that its risk/reward ratio is relatively unfavourable at the present time.

Turnaround stock?

Also recording a falling share price today is Sports Direct (LSE: SPD), with its shares having declined by almost 30% since the turn of the year due in part to its own profit warning. This was at least partly because of challenging performance in its European division and while disappointing, international expansion could still offer improved growth prospects for the company in the long run.

Clearly, Sports Direct is often in the news regarding its staffing policies, but it remains one of the most successful British retailers of recent years. Its business model was able to adapt to the cost of living crisis during the Credit Crunch and now needs to adapt to a UK consumer who has higher disposable income in real terms.

This could be a challenge and the company’s share price may come under pressure in the short run as its dirt cheap pricing could hold less appeal with wage growth being higher than inflation. But Sports Direct’s price-to-earnings growth (PEG) ratio of 1 indicates that it could become a top notch turnaround stock.

Better times ahead?

Similarly, AstraZeneca (LSE: AZN) is also enduring a very challenging period at the present time, with the pharmaceutical company being forced to come to terms with a patent cliff that has caused a severe decline in its earnings in recent years. Looking ahead, this is set to continue, with AstraZeneca expected to report a fall in its bottom line of 6% in the current year.

However, while this is disappointing, the market appears to be looking further out to AstraZeneca’s expected turnaround. With its pipeline gaining momentum through multiple acquisitions and drug development/approval news being relatively encouraging (as recent news has shown), investor sentiment could improve and push the company’s share price higher after its decline of 4% in the last year. And with AstraZeneca trading on a P/E ratio of 15.9, it continues to offer excellent turnaround potential.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca and Sports Direct International. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Is the JD Sports share price set to explode?

Christopher Ruane considers why the JD Sports share price has done little over the past five years, even though sales…

Read more »

Middle-aged black male working at home desk
Investing Articles

The Anglo American share price dips on Q1 production update. Time to buy?

The Anglo American share price has fallen hard in the past two years, after a very tough 2023. But I…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

£9,000 in savings? Here’s how I’d aim to turn that into a £12,300 annual passive income

This Fool explains how he'd target thousands of pounds in passive income every year by investing in high-quality businesses.

Read more »

Market Movers

Why is the FTSE 100 at all-time highs?

Jon Smith flags up two reasons for the jump in the FTSE 100 over the past week, also pointing out…

Read more »

A couple celebrating moving in to a new home
Investing Articles

The Taylor Wimpey share price rises on housing market ‘stability’. Time to consider buying?

The 2024 Taylor Wimpey share price hasn't been in great form, so far. But Paul Summers remains cautiously optimistic for…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

The FTSE 100 reaches an all-time high! Here are 2 of its best stocks to consider buying

With the FTSE 100 soaring in 2024, this Fool thinks investors should consider buying these two stocks. Here he breaks…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Here’s why I see cheap UK shares soaring in the years ahead

UK shares look undervalued and this Fool plans to take advantage of it. Here he details one stock he's keen…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Dividend Shares

Is Legal & General the best stock to buy in the FTSE right now?

UK investors have been piling into Legal & General in recent weeks. But are there better FTSE shares to buy…

Read more »